Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow the Fastest amongst all En

Frost & Sullivan's recent analysis finds that digital therapeutics (DTx) in the United States are considered legitimate alternatives to traditional pharmacotherapy. These solutions are comprehensively regulated and granted prescription status by various national or state-level regulatory agencies based on reported evidence of improved clinical outcomes for a defined patient population.

Life Sciences’ Contribution to the US Digital Therapeutics Market to Grow (frost.com)